RXRX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
18.6M
+141.9%
7.7M
+18.5%
6.5M
-81.8%
35.5M
+586.7%
5.2M
Cost of Revenue
10.0M
-12.6%
11.5M
-8.0%
12.5M
-12.5%
14.3M
-2.8%
14.7M
Gross Profit
8.5M
+322.6%
-3821000
+36.5%
-6018000
-128.3%
21.3M
+323.5%
-9512000
Operating Expenses
131.7M
+0.4%
131.1M
+7.1%
122.5M
-5.5%
129.6M
-20.3%
162.7M
R&D
99.1M
+10.6%
89.6M
+2.0%
87.9M
-8.4%
95.9M
-20.8%
121.1M
SG&A
32.6M
-21.6%
41.5M
+20.1%
34.6M
+2.8%
33.7M
-19.1%
41.6M
Operating Income
-123176000
+8.7%
-134968000
-5.0%
-128505000
-18.6%
-108334000
+37.1%
-172202000
EBITDA
-106641000
+8.7%
-116801000
-7.3%
-108832000
-22.5%
-88856000
+41.2%
-151159000
Net Income
-119036000
+9.1%
-131005000
-11.5%
-117504000
-8.7%
-108122000
+33.4%
-162253000
EPS (Basic)
$-0.22
+12.0%
$-0.25
-13.6%
$-0.22
-4.8%
$-0.21
+41.7%
$-0.36
EPS (Diluted)
$-0.22
+12.0%
$-0.25
-13.6%
$-0.22
-4.8%
$-0.21
+41.7%
$-0.36
Shares (Diluted)
543.0M
+2.0%
532.5M
+0.6%
529.3M
+1.3%
522.7M
+16.9%
447.0M
Recursion Pharmaceuticals (RXRX) — Financials